Alnylam Q2 Revenue Surge Reinforces AMVUTTRA Trajectory, But Risks Linger

What happened

Alnylam reported second-quarter 2026 global net product revenue of approximately $1.2 billion, a 74% year-over-year increase fueled by AMVUTTRA’s continued uptake in ATTR cardiomyopathy. This print lands well above the previous quarter’s $851 million and aligns with the upper end of the company’s FY2026 combined net product revenue guidance of $4.9–$5.3 billion. The strong showing diminishes the sensitivity to small quarterly misses that had previously rattled the stock, but it does not eliminate the overhang from the government price-reporting subpoena or intensifying competition from BridgeBio’s Attruby. While the revenue trajectory supports a base-to-bull case, the market is already pricing in successful scaling, leaving little room for execution error. Confirmation in the next 1–2 quarters, along with no adverse legal developments, would be needed to shift the investment stance from WAIT to ACCUMULATE.

Implication

If Alnylam continues to deliver quarterly revenue in line with or above the $1.2 billion run rate, the FY2026 guidance will appear conservative, supporting a bull case of $5.3 billion or more. However, sustainability depends on maintaining net price amid payer pushback and competitive new-start share. The subpoena over government price reporting remains a material tail risk that could compress gross-to-net economics. Investors should look for evidence of durable demand beyond early adopters and for any signs of legal escalation that could force structural pricing changes.

Thesis delta

Q2 2026 results strengthen the conviction that AMVUTTRA can achieve the guided revenue range, shifting the probability slightly toward the bull scenario. The thesis still requires proof of persistent new-patient adds and stable net pricing, but the risk of a near-term guidance miss has diminished.